- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 63
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- No Condition
- Interventions
- CLAIR
- Other
- Lead sponsor
- Toku Eyes Ltd
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 942 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Canton, Ohio
- Conditions
- ASCVD, Hyperlipidemia, Hypertension
- Interventions
- Referral to the Duke Cardiometabolic Prevention Clinic
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cardiovascular Disease
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 332
- States / cities
- Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 266 more
- Conditions
- Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 285,327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- ASCVD, Coronary Artery Calcification
- Interventions
- Notification of patients and clinicians
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- ASCVD
- Interventions
- Pharmacist call
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Wilmington, Delaware • Durham, North Carolina
- Conditions
- ASCVD Management
- Interventions
- Pharmacy Intern Counseling
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 205
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 158 more
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- bempedoic acid
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
- Conditions
- ASCVD, LDL-C
- Interventions
- Care Champion Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hyperlipemia, Mixed, ASCVD
- Interventions
- Alert
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- ASCVD
- Interventions
- Not listed
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 126 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
- Interventions
- Lepodisiran Sodium, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 222
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
- Conditions
- Type 2 Diabetes, Overweight, ASCVD
- Interventions
- Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60,000 participants
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Placebo, Olpasiran
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 7,297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Lp(a) Screening
- Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
- Conditions
- Cardiovascular Disease
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 101
- States / cities
- Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
- Conditions
- ASCVD, NSTEMI, STEMI, Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina, Chest Pain
- Interventions
- Telehealth Group Counseling
- Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lipoprotein Disorder
- Interventions
- Kylo-11 or matched placebo
- Drug
- Lead sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • Santa Maria, California + 13 more
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- bempedoic acid, placebo
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 779 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Clearwater, Florida • Georgetown, Texas
- Conditions
- Hyperlipidemias
- Interventions
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
- Combination Product · Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
- Drug · Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Obicetrapib, Placebo
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 199
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 161 more